KYTX Kyverna Therapeutics, Inc.

QT16

Latest market price

5.38

+0.16+3.07%

Overview Short InterestFilings

KYTXQT16Kyverna Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

5.38+3.07%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE+0.30%$23.04 RARE+2.39%$16.69 NUVB+2.35%$4.70 TRAX+1.17%$45.58 NTLA+3.95%$12.12 ABSI+5.42%$10.21 URGN-0.50%$34.19 MAZE+1.94%$30.96

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.94	Insider Own	—	Shs Outstand	61.84M	Perf Week	-0.95%

Market Cap	322.82M	Forward P/E	—	EPS next Y	-3.12	Insider Trans	0.00%	Shs Float	28.00M	Perf Month	-16.08%

Enterprise Value	155.82M	PEG	—	EPS next Q	-0.68			Short Float	34.08%	Perf Quarter	-32.90%

Income	-153.00M	P/S	—	EPS this Y	—			Short Ratio	11.28	Perf Half Y	-42.00%

Sales	0.00	P/B	1.94	EPS next Y	—	ROA	-69.44%	Short Interest	9.54M	Perf YTD	-44.47%

Book/sh	2.68	P/C	1.62	EPS next 5Y	—	ROE	-81.91%	52W High	13.67 -60.64%	Perf Year	-22.67%

Cash/sh	3.22	P/FCF	—	EPS past 3/5Y	—	ROIC	-80.05%	52W Low	5.09 5.70%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	8.01% 6.23%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	0.40	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	9.06	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	34.70	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	9.06	EPS Q/Q	35.05%	SMA20	-10.44%	Beta	2.15	Target Price	25.00

Payout	0.00%	Debt/Eq	0.19	Sales Q/Q	—	SMA50	-23.70%	Rel Volume	0.98	Prev Close	5.22

Employees	149	LT Debt/Eq	0.19	Earnings	Nov 11	SMA200	-35.33%	Avg Volume	834.76K	Price	5.38

IPO Date	Feb 09, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.12% —	Net Debt/EBITDA	—	Volume	822,256	Change	3.07%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-25-26	Reiterated	Needham		$25
May-15-26	Reiterated	HC Wainwright & Co.	Buy	$20 → $25
Dec-16-25	Reiterated	Wells Fargo	Overweight
Dec-15-25	Reiterated	UBS
Dec-15-25	Reiterated	Morgan Stanley	Overweight	$25
Dec-04-25	Reiterated	Morgan Stanley	Overweight	$25
Oct-27-25	Reiterated	HC Wainwright & Co.	Buy	$10 → $20
Aug-29-25	Reiterated	HC Wainwright & Co.	Buy	$10
May-27-25	Upgrade	HC Wainwright & Co.	Neutral → Buy

Latest News· Times ET

Oct-28-26

Oct-28-2608:53AM

Kyverna Therapeutics: Fascinating CAR-T Science, Tricky Commercial OutlookSeekingAlpha

Oct-23-26

Oct-23-2610:30AM

Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026globenewswire.com

06:31AM

Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026Benzinga

Oct-22-26

Oct-22-2602:20PM

Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com

Oct-21-26

Oct-21-2607:15AM

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Torontoglobenewswire.com

Oct-07-26

Oct-07-2608:00AM

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026globenewswire.com

Oct-05-26

Oct-05-2604:05PM

BioMarin Appoints Cara Bauer as Chief People OfficerYahoo

Oct-03-26

Oct-03-2604:28AM

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated “Moderate Buy” by Sell-Side Brokeragesdefenseworld.net

Sep-24-26

Sep-24-2601:49PM

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcriptseekingalpha.com

12:32PM

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - SlideshowSeekingAlpha

06:00AM

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravisglobenewswire.com

Sep-14-26

Sep-14-2606:31PM

Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha

Sep-02-26

Sep-02-2604:05PM

Kyverna Therapeutics to Present at Upcoming Investor Conferencesglobenewswire.com

Aug-14-26

Aug-14-2609:18AM

Adicet Bio: A Cheap Gamma Delta T-Cell PlaySeekingAlpha

Aug-13-26

Aug-13-2610:00AM

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approvalseekingalpha.com

Company

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	0	0	0	0	—	—
Cost of Goods Sold Incl. D&A	0	0	2	2	—	—
Gross Profit	0	0	-2	-2	—	—
Selling, General and Administrative Excl. Other	43	36	30	12	—	—
Research and Development	115	134	112	48	—	—
Other Operating Expense	1	0	-2	1	—	—
Operating Income	-159	-170	-143	-62	—	—
Interest Expense	2	0	0	0	—	—
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	8	9	15	2	—	—
Net Income Before Taxes	-153	-161	-127	-60	—	—
Income Taxes	0	0	0	0	—	—
Consolidated Net Income	-153	-161	-127	-60	—	—
Net Income From Continuing Operations	-153	-161	-127	-60	—	—
Net Income	-153	-161	-127	-60	—	—
EPS (Recurring)	-2.94	-3.64	-3.33	-0.00	—	—
EPS (Basic, Before Extraordinaries)	-2.94	-3.64	-3.33	-0.00	—	—
EPS (Diluted)	-2.94	-3.64	-3.33	-0.00	—	—
EBITDA	-149	-159	-125	-58	—	—
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—
Shares Outstanding	61	44	38	674	—	—
Market Capitalization	328	414	142	—	—	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22
Westlake BioPartners Opportunity Fund I, L.P.	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17
Walker Karen Marie	Chief Technology Officer	Jun 06 '24	Option Exercise	4.42	9,636	42,591	9,636	Jun 10
Jones Ryan Alexander	Chief Financial Officer	May 28 '24	Option Exercise	0.73	18,016	13,152	43,950	May 29
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553	Feb 14
Bain Capital Life Sciences Investors, LLC	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868	Feb 14
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000	Feb 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.